genentech – Talk Bio

Genentech (Roche) Signs $420 Million Deal With OMass Therapeutics for Preclinical IBD Program

2 weeks ago talkbio0Tagged Drug Discovery, genentech, Inflammatory Bowel Diseases, milestone payments, OdyssION platform, OMass, Partnership, preclinical program, Roche (company), small molecule therapy

Genentech; Roche; OMass Therapeutics; inflammatory bowel disease (IBD); preclinical program; biotech partnership; OdyssION platform; small molecule therapy; drug discovery; milestone payments

Genentech’s $700M North Carolina Plant and Telix’s FDA CRL Update

3 weeks ago talkbio0Tagged biomanufacturing, Complete Response Letter, CRL, genentech, Holly Springs, Manufacturing Facilities, Medicinal product acting as imaging agent (product), metabolic medicines, North Carolina, Obesity, Roche (company), Telix, United States Food and Drug Administration

Genentech; Roche; North Carolina; manufacturing facility; $700 million; Holly Springs; metabolic medicines; obesity treatments; biomanufacturing; Telix; FDA; Complete Response Letter (CRL); imaging agent

Genentech to End $2B Cell Therapy Collaboration with Adaptive Biotechnologies

1 month ago talkbio0Tagged Adaptive Biotechnologies, Cell Therapy, Collaboration termination, genentech, personalized cancer, T-Cell Receptor, TruTCR

Genentech; Adaptive Biotechnologies; cell therapy; collaboration termination; T-cell receptor; TruTCR platform; personalized cancer therapy; $2 billion deal

Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends

1 month ago talkbio0Tagged Bicycle, Financial cost, genentech, layoffs, Partnership, R&D, strategic realignment, Workforce reduction

Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment

FDA Rejects Roche’s Columvi for Earlier-Line Diffuse Large B-Cell Lymphoma

2 months ago talkbio0Tagged Accelerated, Approved, Columvi, Complete, Diffuse Large B-Cell Lymphoma, gemcitabine, genentech, oxaliplatin, Rejection, Response Letter, Roche (company), second, second-line treatment, STARGLO, Third line treatment, United States Food and Drug Administration

FDA rejection; Columvi; Roche; Genentech; diffuse large B-cell lymphoma; DLBCL; STARGLO study; second-line treatment; Complete Response Letter; gemcitabine; oxaliplatin; accelerated approval; third-line therapy